Dynamics of laboratory markers of endothelial dysfunction in patients with psoriatic arthritis under the influence of the interleukin-17A inhibitor netakimab

QR Code

Dynamics of laboratory markers of endothelial dysfunction in patients with psoriatic arthritis under the influence of the interleukin-17A inhibitor netakimab

Objective: a comparative evaluation of the effect of the interleukin-17A inhibitor (iIL) netakimab (NTK) and methotrexate (MTX) on laboratory markers of endothelial dysfunction in patients with psoriatic arthritis (PsA) in comparison with the dynamics of clinical efficacy indicators during 6 months...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Petrov, O. A. Pritulo, A. A. Petrov
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2024-12-01
Series:	Современная ревматология
Subjects:	psoriatic arthritis endothelial dysfunction methotrexate netakimab vascular endothelial growth factor endothelin 1 nitric oxide
Online Access:	https://mrj.ima-press.net/mrj/article/view/1668
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study
by: T. V. Korotaeva, et al.
Published: (2020-11-01)

Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2021-03-01)

Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2024-08-01)

THE INVOLVEMENT OF ENDOTHELIAL DYSFUNCTION MARKERS IN THE PATHOGENESIS OF CHRONIC GLOMERULONEPHRITIS
by: T.V. Margieva, et al.
Published: (2006-03-01)

Endothelial dysfunction role in atherosclerosis pathogenesis
by: E. N. Vorobyeva, et al.
Published: (2006-12-01)

Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01)

Importance of biological markers in the assessment of endothelial dysfunction
by: Yu. S. Timofeev, et al.
Published: (2024-10-01)

The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice
by: I. M. Marusenko, et al.
Published: (2021-06-01)

Shear Stress-Dependent Modulation of Endothelin B Receptor: The Role of Endothelial Glycocalyx Heparan Sulfate
by: Camden Holm, et al.
Published: (2025-07-01)

ENDOTHELIAL DYSFUNCTION AS CORNERSTONE OF CARDIOVASCULAR EVENTS: MOLECULAR AND PHARMACEUTIC ASPECTS
by: V. V. Kireeva, et al.
Published: (2014-10-01)

ENDOTHELIAL DYSFUNCTIONS AND THEIR CORRECTION IN WOMEN WITH EARLY POSTMENOPAUSE
by: S. N. Tolstov, et al.
Published: (2017-05-01)

Changes in serum NO, ET-1, and VEGF after cannulated screw fixation in patients with femoral neck fractures and their relationship with femoral head necrosis
by: Ziqiang Li, et al.
Published: (2025-07-01)

The effectiveness of complex treatment of endothelial dysfunction in patients with primary open angle glaucoma
by: A. M. Dusmukhamedova, et al.
Published: (2024-10-01)

Methotrexate in a psoriatic arthritis patient
by: K. V. Aleksanyan, et al.
Published: (2016-09-01)

Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis
by: A. V. Rudakova, et al.
Published: (2021-07-01)

Endothelial dysfuncton and 2 type diabetes: novel markers for earlier diagnostics
by: I. A. Khripun, et al.
Published: (2016-10-01)

The role of arginine and endothelial nitric oxide synthase in the pathogenesis of Covid-19 complicated by metabolic syndrome
by: L. A. Kuznetsova, et al.
Published: (2022-12-01)

Endothelium Protective Function of Statins in Men and Women with Coronary Atherosclerosis
by: M. V. Klimushina, et al.
Published: (2016-11-01)

PROGNOSTIC SIGNIFICANCE OF ENDOTHELIAL DYSFUNCTION MARKERS IN ARTERIAL HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2018-05-01)

EFFECT OF FUROSTANOL GLYCOSIDES FROM CULTURED DIOSCOREA DELTOIDEA CELLS ON REGULATORY FUNCTION OF ENDOTHELIUM IN A RAT MODEL OF HYPOESTROGEN-INDUCED ENDOTHELIAL DYSFUNCTION
by: E. B. Artyushkova, et al.
Published: (2016-01-01)

ACTIVITY MODULATION OF VARIOUS NITRIC OXIDE SYNTASES AS AN APPROACH TO ENDOTHELIAL DYSFUNCTION THERAPY
by: D. V. Kurkin, et al.
Published: (2022-05-01)

ENDOTHELIAL DYSFUNCTION IN ISCHEMIC HEART DISEASE
by: N. E. Zakirova, et al.
Published: (2016-01-01)

Nitric oxide role and endothelial dysfunction development in diabetes mellitus
by: S. G. Dzugkoev, et al.
Published: (1970-01-01)

Role of nitric oxide and endothelial NO synthase in carcinogenesis
by: V. P. Deryagina, et al.
Published: (2021-07-01)

Methods for diagnosing endothelial dysfunction
by: A. V. Shabrov, et al.
Published: (2021-07-01)

Relation of smoking and endothelial dysfunction markers in systemic hypertension
by: V. I. Podzolkov, et al.
Published: (2018-10-01)

Lead acetate deteriorates the improvement effect of L-arginine and tetrahydrobiopterin on endothelin-1 receptors activity in rat aorta
by: Zhikal Omar Khudhur, et al.
Published: (2023-10-01)

CLINICAL IMPORTANCE OF ENDOTHELIAL DYSFUNCTION AND INSULIN RESISTANCE SYNDROME IN PATIENTS WITH GOUT ASSOCIATED WITH ARTERIAL HYPERTENSION
by: N. N. Kushnarenko, et al.
Published: (2015-09-01)

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
by: A. M. Dadalova, et al.
Published: (2020-11-01)

Novel Biomarkers of Endothelial Dysfunction in Cardiovascular Diseases
by: Z. M. Abdurakhmanov, et al.
Published: (2021-09-01)

Endothelial function vessel wall measures in patients with gout associated with coronary heart disease
by: E S Feofanova, et al.
Published: (2007-06-01)

Endothelial dysfunction. Do we understand this term properly?
by: T. D. Vlasov, et al.
Published: (2020-05-01)

Endothelial dysfunction in acute renal injury in children with hemolytic-uremic syndrome (literature review)
by: E. V. Gunkova, et al.
Published: (2021-06-01)

CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC COR PULMONALE BY ANGIOTENSIN II RECEPTORS ANTAGONISTS
by: V. S. Zadionchenko, et al.
Published: (2015-12-01)

SARS-CoV-2 (MA10) Infection Aggravates Cerebrovascular Pathology in Endothelial Nitric Oxide Synthase-Deficient Mice
by: Saifudeen Ismael, et al.
Published: (2025-05-01)

Cytokine profile in psoriatic arthritis: search for relationships with inflammation and blood rheological properties
by: Tat'yana Viktorovna Korotaeva, et al.
Published: (2011-02-01)

The Role of Endothelial Progenitor Cells (EPCs) and Circulating Endothelial Cells (CECs) as Early Biomarkers of Endothelial Dysfunction in Children with Newly Diagnosed Type 1 Diabetes
by: Milena Jamiołkowska-Sztabkowska, et al.
Published: (2025-07-01)

CLINICAL AND DIAGNOSTIC VALUE OF STUDIES OF ENDOTHELIAL DYSFUNCTION MARKERS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: A. Kh. Akhmineeva, et al.
Published: (2014-02-01)

Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study
by: Arfenya E. Karamova, et al.
Published: (2025-06-01)

ACE INHIBITORS ARE RATIONAL PHARMACOTHERAPY OF ENDOTHELIAL DYSFUNCTION
by: M. P. Metrova, et al.
Published: (2016-01-01)